Curatek Pharmaceuticals Report issue

For profit Phase 3
Founded: Elk Grove Village IL United States (1994)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2015
NCT02308033
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Curatek Pharmaceuticals, LLC

Active Ingredients

Drugs in Phase 3 Trials (2)

metronidazole (flagyl) (2 trials)

terconazole (terazol) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2